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Abstract 
Background and objectives: There are few studies of the prevalence of epilepsy in Canada, and 
there is no available estimate of the incidence and mortality of epilepsy in all age groups in the 
Canadian population. This study aimed to measure the incidence, prevalence, mortality and the 
temporal trends for epilepsy in Saskatchewan between 2005 and 2010. Methods: The study used 
a population-based, retrospective cohort design with information from the Saskatchewan’s 
Population Health Registry databases for the periods of January 01, 2005 to December 31, 2010. 
The study cohort included the covered entire population of Saskatchewan with the identification 
of patients with epilepsy based on ICD codes. The incidence rate, prevalence, and standardized 
mortality ratio of epilepsy were measured over a period of six years and annually between 2005 
and 2010 and age-standardized with the 2006 Canadian population. Results: The crude cumulative 
incidence of epilepsy was 63 per 100,000 person-years (age-standardized rate 62 per 100,000 
person-years). Age-specific incidence was highest in the 75-79 age group (133.5 person 100,000 
person-years). There was a significant decrease in the incidence of epilepsy over the study period. 
The incidence in self-declared Registered Indians (RI) was 95 per 100,000 person-years (age-
standardized rate 122 per 100,000 person-years). It was significantly higher than the general 
population in most of the age groups. The overall prevalence was 8.5 in 1,000 people (9 per 1,000 
if age-standardized to the 2006 Canadian population) with a male prevalence of 9 and a female 
prevalence of 8.4 per 1,000 person-years. There was a significant increase in the prevalence over 
time. The age-specific prevalence was high in 15-19 age group, 35-39 age group, and 80-84 age 
group. The cumulative SMR for the total group was 2.45 (2.7 in males and 2.2 in females). Age-
specific SMRs were highest in the 10-14 age group. There was no temporal change in the SMR 
over the study period. Discussion: The findings of this study are consistent with incidence, 
prevalence and mortality studies from developed countries. However, the decrease in the incidence 
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of epilepsy over time has been only seen previously in Nordic countries and needs more research. 
Significance: This study was the first in Canada to measure the incidence and all-cause mortality 
of epilepsy in all age groups. It provides core indicators of public health and healthcare needs of 
patients with epilepsy in Saskatchewan and Canada. 
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CHAPTER 1: INTRODUCTION 
1.1 Background 
Epilepsy is a common chronic medical and social disorder with unique characteristics. It 
is usually defined as a disease of the brain characterized by its predisposition to generate recurrent 
seizures (1). Epilepsy is one of the most prevalent neurological conditions affecting some 50 
million people worldwide (2). Moreover, this disease knows no geographical, racial or social 
boundaries, affecting people irrespective of sex and age (3). Epilepsy explains 1% of the global 
burden of disease, where the burden of disease is determined by the number of productive life 
years lost as a result of disability or premature death (3). Accordingly, epilepsy’s burden is similar 
to that of breast cancer in women and lung cancer in men (2). 
To understand a disease like epilepsy, knowledge about its distribution in the populations 
and factors that influence or determine its distribution is critical (4,5). Epidemiology is the basic 
science of medicine which studies the distribution of the disease. Epidemiology uses mortality and 
morbidity rates such as disease incidence (number of new cases of epilepsy that occur during a 
defined period) and disease prevalence (the number of affected persons present in a population at 
the specific time) as core indicators of public health and healthcare needs of a population.  
1.2 Statement of the problem 
Epilepsy is one of the most common neurological disorders worldwide and responsible for 
20.6 million disability-adjusted life years (DALYs) lost. Patients with epilepsy have increased 
health-care needs, premature death and decreased productivity, and also face stigma and 
discrimination as well as huge gaps in access to care (6,7). In Canada, the overall epidemiology of 
epilepsy has not been well characterized. Of the few studies that have examined the epidemiology 
of epilepsy, most have been impacted by methodological problems such as self-reported diagnosis 
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of epilepsy, limited age groups (8–14), and restricted syndromes (15–17).  Furthermore, none of 
the available studies have measure the incidence rate, mortality, or temporal trends of epilepsy 
across all age groups. Also, it is highly probable that temporal trends in the epidemiology of 
epilepsy have changed in recent years as a result of updated diagnostic criteria,  the increased use 
of technology such as the electroencephalogram (EEG), Magnetic Resonance Imaging (MRI), and 
the establishment of epilepsy programs in Canada. Provincially, specific epidemiological data for 
the prevalence, incidence rate, and mortality of epilepsy are needed to allocate resources 
efficiently, and to develop new programs and interventions for patients with epilepsy in 
Saskatchewan.   
1.3 Purpose and Objectives 
The purpose of this study is to estimate the overall incidence rate, prevalence, and mortality 
of epilepsy in Saskatchewan, Canada. This study also seeks to describe temporal trends in the 
incidence and prevalence of epilepsy over a period of six years with respect to age, sex, urban 
setting and ethnicity (self-declared Registered Indian (RI) status). 
The specific objectives are: 
1. To measure the yearly crude and standardized incidence rate and prevalence of epilepsy in 
the general population from 2005 to 2010 
2. To describe the incidence of epilepsy stratified by sex, age group, and in Registerer Indians  
3. To estimate the Standardized Mortality Ratio (SMR) for epilepsy 
4. To evaluate temporal trends in incidence, prevalence, and the SMR of epilepsy overa  six-
year period 
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1.4 Research questions 
Specific issues which have a reasonable expectation of being answered from available data 
are indicated below: 
Incidence and prevalence of Epilepsy  
• What are the patterns and temporal trends of incidence and prevalence of epilepsy in 
Saskatchewan by year, age, sex, and RI status from 2005 to 2010?  
Mortality of Epilepsy  
• What is the yearly all-cause SMR in those with epilepsy compared to the general 
population in Saskatchewan from 2005-2010 period by age and sex? 
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CHAPTER 2: LITERATURE REVIEW 
2.1 Epilepsy: an overview 
Epilepsy is a brain disease characterized by the predisposition to recurrent and 
unpredictable epileptic seizures(1) and can have multiple etiologies. An epileptic seizure is an 
abnormal and excessive discharge of brain neurons involving abnormal hypersynchrony between 
them (18). Practically, epilepsy is defined as (1): 
1. At least two unprovoked seizures occurring >24 h apart.  
2. One unprovoked seizure with additional features accompanied with circumstances that 
increase the possibility of a recurrence of seizures such an epileptiform 
electroencephalogram (EEG) study or stroke lesion in an imaging study such as 
Magnetic Resonance Imaging (MRI) or Computed Tomography (CT)).  
3. Diagnosis of an epilepsy syndrome such as Dravet syndrome, childhood absence 
epilepsy or juvenile myoclonic epilepsy  
Epilepsy is generally considered to be resolved in individuals who had an age-dependent 
epilepsy syndrome but are now past the applicable age, or in those individuals who have remained 
without a seizure throughout the last 10 years, with no anti-seizure medication throughout the last 
5 years(1). 
Specific seizures can be categorized by clinical elements (e.g., complex partial seizures 
and generalized tonic-clonic seizures), whereas epilepsy syndromes can likewise be categorized 
by type of seizure, the presence or absence of neurologic or developmental abnormalities, and EEG 
findings (19). 
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Epilepsy syndromes fall into two general classifications:  generalized and partial (or 
localization-related) syndromes. In generalized epilepsies, the main type of seizures starts at the 
same time in both cerebral hemispheres. Most generalized epilepsies have a significant 
hereditary component and are associated with the normal neurologic function. On the other hand, 
in partial epilepsies, seizures start in one or more restricted foci, but may then spread to include 
the whole brain. Most partial epilepsies are thought to be the result of one or more brain injuries, 
although most of the cases the etiology is unknown (19). 
Epilepsy is known in almost every culture and has been documented for thousands of 
years. Epilepsy may occur at any age (20) and affects around 50 million people worldwide. 
Unfortunately, in spite of its pervasiveness, frequent treatment failures, and poorly understood 
mechanisms, the condition receives moderately little research funding (21). 
The historical backdrop of epilepsy was summarized by the neurologist Rajendra Kale 
who wrote:  
 “4,000 years of ignorance, superstition, and stigma followed by 100 years of knowledge, 
superstition, and stigma (22).” 
Epilepsy affects all aspects of the life of a person, including safety, memory, cognition, 
and mood. Social aspects such as driving, employment, and stigma may profoundly affect overall 
functioning. People with epilepsy (PWE) have worse quality of life, family function, and social 
support than people with other chronic diseases (8,23). Finally, PWE’s are high users of 
healthcare facilities including the emergency room, hospital in patient beds, psychologist/ 
psychiatric specialists, social workers, nursing services and other health professionals (8). 
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2.2 Epidemiology of Epilepsy 
Epidemiology is the study of the distribution, determinants and natural history of a medical 
condition in a population (5). The epidemiology of epilepsy is largely based on descriptive and 
analytical studies, as very little experimental work has been carried out on humans for various 
reasons, including logistical and ethical. Despite epilepsy being amongst the most common serious 
neurological conditions, there are many gaps in our understanding of its epidemiology. These 
deficiencies are partly due to methodological problems and also due to the failure to take fully into 
account epilepsy's heterogeneous nature (24). 
Epilepsy is distributed unequally around the world. These dissimilarities have been 
attributed to varying exposures to various environmental factors such as malaria, 
neurocysticercosis, and injuries (particularly road traffic and birth-related injuries). Epidemiologic 
patterns of epilepsy are affected by differences in socioeconomic factors such as medical 
infrastructure, availability of preventative health programs and available care (25). Another source 
of discrepancy might be variations in the definition of epilepsy and discrepant methods of case 
ascertainment. For example, in 2005, the practical clinical definition of epilepsy was amended. 
The new definition included the previous definition of two unprovoked seizures >24hr apart but 
also included two additional criteria: 1. One unprovoked seizure accompanied with circumstances 
that increase the possibility of a recurrence of seizures such an epileptiform EEG study or stroke 
lesion in an imaging study and 2. The diagnosis of a known epilepsy syndrome such as West or 
Lennox-Gaustaut syndrome (18). This broadened definition would be expected to result in an 
increased incidence and prevalence of epilepsy compared to previous prevalence data in the 
Canadian population. 
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2.2.1 Incidence of epilepsy in developed countries 
There are relatively few population-based studies of the incidence of epilepsy. In developed 
countries, the overall cumulative incidence of epilepsy is thought to be around 50 per 100 
000/person-years (range 40-70 per 100 000/person-years) (26,27). Industrialized countries seem 
remarkably consistent across geographic areas for at least the last two decades.   
Age 
Most of the studies that report the incidence of epilepsy have been conducted in specific 
age groups such as children (13,28–34), adults (35–42) and elderly (40,41,43,44). In general, the 
information is consistent with the incidence in population-based studies. Epilepsy most commonly 
has its onset at the extremes of life. In developed countries it follows a U-shaped distribution with 
high incidence in the first few months of life, much lower incidence after the first year of life and 
then the highest incidence in the elderly (45). Only 50% of the cases of epilepsy start in later 
childhood or adolescence (27).  
In children, it is speculated that improvements in prenatal care with advances in neonatal 
monitoring units (36) as well as healthier lifestyles of expectant mothers (46) could explain 
decreases in incidence over the time. 
The high incidence of epilepsy in elderly individuals is likely related to the presence of 
comorbid conditions, specifically cerebrovascular diseases. Indeed, epilepsy is related to all the 
pathological spectrum of cerebrovascular diseases (small-vessel to major arterial occlusion), 
although it is more likely to be associated with larger cortical hemorrhagic areas of infarction (47).  
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The elderly are also prone to other disorders associated with epilepsy such as non-vascular 
dementias, tumors (brain and metastases), trauma, infections, and metabolic disturbances (47), 
which might increase the overall prevalence with age.  
Sex 
In most  population studies the incidence of epilepsy is between 1.1 and 1.5 times greater 
in males than in females (48,49). This difference appears to be due to many of the major risk 
factors for epilepsy (i.e., head injury, stroke, central nervous system infection) being more frequent 
in males. Although in most but not all incidence studies, sex-specific differences in incidence have 
not been statistically significant, the consistency of the male-to-female differences across studies 
suggests that this is a true finding (45). 
Race 
Most of the population incidence studies have been performed in very ethnically 
homogeneous populations. There are few studies exploring possible racial differences. One of 
these studies determined the incidence and prevalence of epilepsy among elderly (65 yrs. or older) 
Medicare beneficiaries in the United States. The authors found that the elderly population of Native 
Americans had a statistically lower incidence of epilepsy (1.1 per 1,000) compared with white 
beneficiaries (2.3 per 1,000) (50). 
Elderly African-Americans patients had up to an eight-fold higher risk of epilepsy than 
their Caucasian counterparts. Also, they did not find any incident cases among the elderly Asian 
and Native American group (51). This may be a result of the small numbers of elderly Native 
Americans. Native Americans have been found to the lowest life expectancy rate of all group, with 
a life expectancy of 71 years, which is six years less than the life expectancy in the white (sic) 
population (52). 
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2.2.1.1 Canadian incidence of epilepsy studies 
One of the few studies measuring the incidence of epilepsy in Canada was conducted by 
Camfield et al. This study measured the incidence of epilepsy among children between one month 
and 16 years in the province of Nova Scotia from 1977 to 1985 (13).  The authors identified cases 
through electroencephalography (EEG), records assuming that all the children with two or more 
unprovoked seizures previously seen by a physician would have an EEG available. The authors 
gathered the details of each case from the hospital neurologist’s chart, or by a phone call to the 
family doctor or the parent or patient. The age-specific incidence rates were higher in the first year 
of life (118 per 100,000) followed by a plateau between the age of one and ten years (46 per 
100,000). After age ten the incidence decreased dramatically and approached that of adults. There 
were differences in the incidence of epilepsy by sex depending on the epilepsy type. Females had 
higher incidences of absence seizures, myoclonus, infantile spasm, tonic, a-kinetic drop episodes 
or atypical absence seizures, but there was no difference between females and males in generalized 
tonic-clonic seizures and partial or partial secondarily generalized seizures types. 
 There are two more Canadian studies measuring the incidence of seizures. One is the study 
by Ronen et al. This study estimated the incidence of neonatal seizures in all obstetric and neonatal 
units in Newfoundland from January 1, 1990, to December 31, 1994. The incidence of neonatal 
seizures was reported as 2.6 per 1,000 live births (10). However, it is important to note that 
neonatal seizures often have an acute cause (provoked seizures) which would eliminate them for 
the diagnosis of epilepsy. The second study is the study by Brna et al. (15) This study measured 
the incidence of infantile spasms (IS) in the provinces of Nova Scotia and Prince Edward Island 
from 1978 to 1998(15), using EEG records, discharge diagnosis (ICD codes), chart review and 
10 
previous cohort study of childhood epilepsy. The overall incidence of IS was found to be 30.7 per 
100,000 live births with a higher incidence (not statistically significant) in males than females (15). 
2.2.2 Temporal trends in the incidence of epilepsy 
Few studies have examined variations in the rates of epilepsy over time. Secular changes 
in the incidence of epilepsy are critical to understanding, as they may clarify changes in risk factors 
or uncover changes in clinical practice such as modifications in definitions, improvement in 
technology for detection and treatment, or increased awareness of the disease. One of the few 
articles published on this matter is the study by Hauser et al. (36) in Rochester, USA. This study 
measured the incidence of epilepsy over a 50 year period and reported a 40% decrease in the 
incidence of epilepsy in children under ten years between the decades 1935-1944 and 1955-1964, 
but a doubling of the incidence in adults older than 60 years between 1974 and 1984 (36). 
More recently, the study in Tonbridge's pediatric population (<20 years) by Cockerell et 
al. in 1995 found a decrease in the incidence of epilepsy from 152.4 per 100,000 person-years in 
the period 1974-83 to 60.9 per 100,000 person-years in the period 1984-93 (53). 
Among adults in Sweden (> 17 years), Forsgren et al. identified an increase in the incidence 
of epilepsy from 34 per 100 000 people (in the period of 1985-1987) to 47- 56 per 100 000 people 
in the period of 1992-1994 (35), although there are no definitive explanations for these changes. 
Hauser et al. (36) speculate that these changes might be related to major advances in the diagnosis 
and treatment of epilepsy.  
2.2.3 Prevalence of epilepsy in developed countries 
Because cross-sectional studies are easier and cheaper to conduct there are many more 
prevalence studies of epilepsy than of incidence; indeed, prevalence studies have been carried out 
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in more than 25 countries in all five continents (34,48,49,53–84). Moreover, most studies which 
do provide data on incidence also report prevalence. In relatively unselected populations in 
developed countries, the prevalence of epilepsy is found to be between 4 and 10 per 1,000 persons 
(85).  
Age-specific prevalence 
Epilepsy is a disease that can begin at any time of life. The pattern of age distribution in 
the prevalence of epilepsy varies among different countries. In developed countries, the prevalence 
increase during adolescence tends to be stabilize in adulthood and increase with age after 50, with 
the highest prevalence occurring in the elderly (86,87). 
2.2.2.1 Canadian studies in the prevalence of epilepsy 
There have been two recent publications assessing the prevalence of epilepsy in the 
Canadian population. Wiebe et al. (1999) measured the prevalence of epilepsy based on the 1990 
Ontario Health Survey (OHS). The OHS was a large-scale survey sponsored by the Ministry of 
Health which used a questionnaire administered to the residents of Ontario for the first time in 
1990 and repeated in 1996-1997. The sampling procedure was through a multistage, stratified, 
geographic cluster design. Telephone numbers were generated and dialed using random digit 
dialing (RDD) to 30,000 residents of Ontario aged 12 and over. The 1990 survey contained two 
parts; one part was a 22-page interview with only one member of a randomly selected household 
and the second part was a 26-page self-completed questionnaire filled out by each member of the 
household 12 and older (88). This survey did not include persons living on Indian Reserves, 
Canadian Forces bases, those in extremely remote areas, residents of institutions or collective 
dwellings, homeless persons, and those without access to a telephone. The phone questionnaire 
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explored recent or current health problems, use of health services and demographic information.  
In this study, Wiebe et al. found a prevalence of self-reported epilepsy of 5.8 per 1,000 people (8). 
Later on, Tellez-Zenteno et al. (2004) assessed the national and regional prevalence of self-
reported epilepsy in Canada (9) by analyzing data from two cross-sectional national health surveys: 
The National Population Health Survey: Cycle 3 (NPHS) and the Canadian Community Health 
Survey: Cycle 1.1 (CCHS). 
The National Population Health Survey collected information related to the health and 
socio-demographic related descriptors of the Canadian Population. The target population included 
all ages of household residents from all provinces who responded voluntarily to the survey. 
Residents of Indian Reserves, Canadian Forces Bases and remote areas in Quebec and Ontario 
were excluded  (89).The interviews were conducted by telephone in 95% of the cases and 5%  of 
the interviews were in person. All interviews were conducted between 1998 and 1999. Questions 
covered health status, use of health services, determinants of health, chronic conditions, and 
restrictions of activities as well as socio-demographic information. 
The Canadian Community Health Survey was a biennial survey that collected information 
related to health status, health care utilization and health determinants in the population of 12 years 
and older living in the ten provinces and the three Canadian territories.  
Using the information collected in these surveys, Tellez-Zenteno et al. found a general 
prevalence of self-reported epilepsy of 5.2 per 1,000 in NPHS (1998-1999) and 5.6 per 1,000 in 
CCHS (2000-2001) (9). The authors also found a higher prevalence of epilepsy in those at the 
lowest educational level, those with the lowest income, those unemployed in previous years and 
non-immigrants. 
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In general, epilepsy prevalence studies in Canada have been based on population-based 
general health surveys where epilepsy was not the main objective. Moreover, the presence of 
epilepsy was ascertained by self-report with only one question: “Do you have epilepsy?” This 
method may have a resulted in unreliable data because people are not always aware of, or truthful 
about their epilepsy (90). 
Age-specific prevalence 
Both the Ontario Health Survey and the National Population Health Survey data found a 
higher prevalence of epilepsy in older age groups. The youngest group aged 12-14 years had a 
prevalence between 4.4 and 5.7 per 1,000 people; individuals aged 25-44 years had a prevalence 
between 5.9 and 6 per 1,000 people, and the oldest group of >65 years had a prevalence between 
6.9 and 7.2 per 1,000) (8,9). 
Other studies measuring the prevalence of epilepsy in the Canadian population include 
those by Kozyrskyj et al. (91),  Schiariti et al. (14) and Prasad et al.(12).  
The first study from Kozyrskyj et al. in Manitoba (11)  found a general prevalence of 
epilepsy of 4.7 per 1,000 among children under 19 years of age. This study showed a steady 
increase with age in the prevalence of epilepsy from 3.5 per 1,000 people in children under five 
years old to 7.2 per 1,000 children aged 15-19. 
The study of Schiariti et al. in BC  (14) found the prevalence of epilepsy in children under 
19 years of age to be 5.5 per 1,000 people. This study found that the prevalence of epilepsy was 7 
per 1,000 people in those 0-4 years and steadily decreased with age to 5.1 per 1,000 in the 15-19 
years old group. In this study, the highest prevalence, (overall and specifically in the group of 
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infants and pre-schoolers), was thought to be related to a misclassification bias (febrile seizures 
misclassified with epilepsy) and the inclusion of First Nation children (14). 
The third study by Prasad et al. found a prevalence of epilepsy among subjects from 0 to 
13 years old was 4.03 per 1,000 for cycle 2 of the survey and among subjects from 0 to 15 years 
old the prevalence was 5.26 per 1,000 for cycle 3 of the national survey. 
Sex 
Four Canadian studies explored differences in sex (8,9,12,14), but just one of them found 
a statistically higher prevalence of epilepsy in male versus female children ( M:F 6.45:4.00 per 
1,000 children) (12). 
Race 
In British Columbia, Canada, a study using administrative databases found a high 
prevalence of epilepsy in those health regions with a higher proportion of First Nations people 
(35). Similarly, an analysis of administrative data in Alberta (Calgary Health Region) found that 
Aboriginals were more likely than non-aboriginals to visit the Emergency Room (ER) (OR=4.9, 
95% CI 3.2-7.4) or be hospitalized (OR=2.9, 95% CI 2.0-4.3) for epilepsy (92).  
In conclusion, epilepsy is very frequent and affects a very considerable number of people. 
There have been original Canadian studies concerning epidemiological data of epilepsy, but no 
recent studies measuring the incidence and prevalence of epilepsy in all the age groups. 
Furthermore, there is a lack of Canadian studies of temporal trends in epilepsy. 
2.2.6 Mortality of epilepsy in developed countries  
Mortality in people with epilepsy (PWE) has been an important research focus since the 
1930’s (93) . 
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Various different measures have been utilized to calculate mortality in epilepsy, but the 
standardized mortality ratio (SMR) is the most widely recognized measure used to look at 
differences in the rates of death between a population of individuals with epilepsy and the general 
population (94).  
The causes of death in epilepsy may be classified into three groups: a) unrelated causes, b) 
related to an underlying disease, and c) epilepsy-related deaths. The unrelated causes can include 
for example, neoplasms outside the central nervous system, ischemic heart disease or pneumonia. 
Death related to an underlying disease include brain tumors, cerebrovascular disease, and cerebral 
infections. The epilepsy-related category includes deaths directly related to a seizure, treatment, 
and medications as well as status epilepticus, sudden unexpected death i9n epilepsy (SUDEP), 
suicides, trauma, burns, drowning, asphyxiation, aspiration and trauma (95). 
In one systematic review of studies exploring all-causes of death in patients with epilepsy, 
it was found that individuals with epilepsy were between 1.6 to 4.1 times (SMR= 1.6- 4.1) more 
likely to die than individuals in the general population. The review also concluded that males with 
epilepsy had higher mortality rates than females (96) . 
Age-specific mortality 
Most studies have found an inverse relation between SMR and age for all causes of death 
in epilepsy. Epileptic children had the highest, and the elderly had the lowest SMRs (97). In 
children, the SMR reached up to 22.25 (98) in the first year of life and 13.5 in the remaining groups 
of children.  
16 
2.2.6.1 Canadian studies for mortality in epilepsy  
There are three Canadian studies of mortality in epilepsy. One is a population-based study 
for all causes of death in children with epilepsy and the two other studies measured epilepsy-related 
deaths, specifically SUDEP: one in children and one in adults. 
The first study was conducted with the Nova Scotia childhood epilepsy cohort that included 
incident cases of epilepsy between 1977 and 1985 (99). Children aged from 28 days to 16 years 
were included. Children with neonatal seizures were excluded. The authors linked names and birth 
dates to the provincial death and marriage registries. The death certificates and autopsy reports 
were also reviewed for patients known to the authors. 
Within the follow-up group of 686 PWE, 26 deaths were identified. Taking into account 
the reference population of Nova Scotia children and young people, children with epilepsy were 
5.30 times more likely to die in 1980 and 8.80 more likely to die in 1999 than the general 
population (99). 
The second study aimed to calculate the frequency and risk factors for SUDEP in Ontario’s 
pediatric population (less than 18y). Cases of SUDEP were obtained from files of the Ontario 
Chief Coroner’s Office, Ontario Pediatric Forensic Pathology Unit and anecdotal cases from the 
staff in the Division of Neurology at the Hospital for Sick Children in Toronto.  
The authors identified 27 cases of SUDEP from 1988 to 1998 and calculated  a crude rate 
of 2 per 10,000 person-years among children with epilepsy in Ontario in 1998 (16). 
The last Canadian study investigated SUDEP in Saskatchewan among people aged 15 and 
49 years. Cases of SUDEP were identified through hospital discharge codes and from the registry 
file linked to the Saskatchewan Health Database. Death certificates and available autopsy reports 
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were obtained for deaths outside of the hospital and deaths of unknown causes in PWE, death 
certificates and available autopsy reports were also obtained.  
There were 39 cases of SUDEP between 1970 and 1990, giving a maximum overall 
incidence of SUDEP of 1.35 per 1,000 person-year (17). 
Unfortunately, none of the studies measured all-cause mortality in PWE in all age group in 
Canada. 
As individuals responsible for health policy development, implementation, and assessment 
uses this kind of information as a factual source for decision making (100) a study including age-
specific mortality in epilepsy is of great importance. 
Age and cause-specific mortality also provide an instant depiction of the health status of a 
population. Finally, information of temporal trends on mortality (by causes) substantiate the 
progress of health programs.  
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CHAPTER 3: METHODS 
3.1.1 Study population 
Saskatchewan is one of the prairie provinces of Canada covering 651,900 square kilometers 
(6.5% of Canada’s 9,984,670 square kilometers). It shares a border with Alberta to the west, 
Manitoba to the east, Northwest Territories toward the north, and Montana and North Dakota (the 
USA) to the south (101).  
Saskatchewan’s populace (1,033,381 people in 2011) represents approximately 3% of the 
total population of Canada. 
According to the 2011 census population of Saskatchewan, 50.5% of individuals were 
females and 49.5% were males. Children (under the age of 15) accounted for 19 % (197,855 
individuals); the working age population (age 15 to 64 years) accounted for 66% (681,815 
individuals); and seniors (aged 65 and over) accounted for 15% (153,705 individuals). This 
Saskatchewan age distribution is similar to the Canadian distribution by age group (16.7%, 68.5%, 
and 14.8% respectively) (102).  
Also in 2011, Saskatchewan residents largely described themselves as being of European 
ancestry (76%)(103), self-identified Aboriginals (15.6%) (103), and others (8.4%).The largest 
component of self-identified Aboriginal residents were members of First Nations (66.6%) 
followed by Metis people (33.3%). This 16% of the self-identified Aboriginal proportion of 
Saskatchewan population represented the second highest proportion within all provinces in 
Canada, where the proportion of the population was 3.8% (104). 
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In Saskatchewan, all residents receiving medical coverage constituted the “covered 
population” for the present study, which did not include federally insured residents (such as federal 
prison inmates, individuals from the Canadian Forces and Royal Canadian Mounted Police). 
Approval for this study was obtained from the Biomedical Research Ethics Board at the 
University of Saskatchewan (Bio# 15-225). 
3.1.2 Data sources 
The study was conducted using administrative data from the province of Saskatchewan and 
followed standards for epidemiologic studies and surveillance of epilepsy (94).  The government 
of Saskatchewan maintains several databases of health services utilization for beneficiaries, which 
includes up to 99% of the provincial population. Data is linked at the patient-level through a unique 
personal Health Services Numbers for each individual (105).  
The epilepsy database was created through linkage of the following health services claims 
data: Person Registry, Hospital Separation Data, and Physicians services data. 
1. Person Registry: provides information on all residents eligible for Saskatchewan Health 
benefits and provides demographic information about the covered population. 
2. Hospital Separation Data: this includes patient information on every discharge, 
transfer, or in-hospital death in Saskatchewan including diagnoses, procedures, and 
hospital admission/discharge dates. Records of inpatient separations and day surgeries 
for patients treated in hospitals are captured as well as out-of-province hospital 
separations for Saskatchewan health beneficiaries.  
3. Physician’s services data: this includes doctor and nurse practitioner service claims for 
payment from the provincial government for services provided to patients. Patient 
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information is included, as well as service information such as date, fee code, type, 
diagnosis code associated with service (maximum of one diagnosis code per service 
claim), location, and payment information (105). Physicians who are remunerated on a 
non-fee-for-service basis are also expected to submit same ‘shadow,' or ‘dummy’ 
billing claims to evaluate productivity. 
The method of classification for diseases and related health problems in Saskatchewan 
hospitals before April 1, 2002, was based on the 9th revision of the International Classification 
of Diseases (ICD-9), allowing only 16 diagnoses per record (88). ICD-10-CA codes were 
introduced April 1, 2001, after which time approximately 30 % of hospitals in Saskatchewan 
continued to use ICD-9 codes. By April 1, 2002, the transition to ICD-10-CA codes was 
complete, and all hospitals were using this system to record up to 25 diagnoses per record (89). 
The primary data files for this study were created and de-identified by epidemiologists at 
the Saskatchewan Ministry of Health (SMH) Public Health Branch (PHB) through a formal data 
sharing agreement between SMH and the University of Saskatchewan.  
The data released contained a file with individual-level data from individuals with epilepsy 
(study identification, sex, year of birth, status at index (incidence or prevalent), index date, exit 
reason, and registered Indian status); and a file containing information allowing us to establish an 
appropriate denominator from the overall population (calendar date, sex, year of birth, registered 
Indian status, and frequency). 
Registered Indians  
Registered Indians (RI) were identified through a flag in the person registry from self-
declaration to Saskatchewan Health. Information regarding the date of registration (initiation or 
withdrawal) was not reported. 
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Registered Indians or Status Indians are people who are registered with the federal 
government as Indians, which only include First Nation people. RI are entitled to some benefits 
that are not available to Non-Status Indians or Metis people such as on-reserve housing benefits, 
education, and exemption from federal, provincial and territorial taxes in specific situations (106) 
Mortality 
The date of death (month and year) was collected from the Person Health Registry System 
(PHRS) database. This registry requires a Medical Certificate of Death to be filled out by a medical 
examiner, physician or nurse practitioner. It also requires a Medical Statement of Death, which is 
filled out by a funeral director.  It is also possible for the death to be reported directly to PHRS. 
This report needs to be accompanied by proof of the death (i.e., funeral director’s Statement of 
Death).This would occur, for example, in the case of deaths which occur out of the country as the 
registry does not receive notifications for these deaths from any other agency.  
Information on deaths gets uploaded to the PHRS database on a nightly basis. We did not 
receive information about the causes of death. 
3.1.3 Cohort case definition algorithm 
The cohort included individuals with at least two years of continuous provincial health 
coverage between January 1, 1999, and December 31, 2010, and also included children born 
between January 1, 1999, and December 31, 2010. 
The specific criteria used to define cases of epilepsy were as follows: 
1. During the period January 1, 2001, to December 31,2010 the subject had, at least, one 
hospital separation with a diagnosis of epilepsy (ICD-9 345 or ICD-10-Ca G40)  
or 
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2. During the period January 1, 1999, to December 31, 2010, the subject had at least two 
physician visits with a diagnosis of epilepsy (ICD-9 345 or ICD-10-Ca G40) on different 
dates within 730 days; the second of the two physician visits had to be on or after January 
1, 2001. The medical services file was processed until the first pair of physician visit met 
these criteria. When this was met, the date of the first of the two physician visits was taken 
as the case date 
This definition of epilepsy has been assessed in a previous Canadian study that included 
2,253 charts. This study used as a gold standard chart review by two trained physicians in 
epilepsy management to determine if the patient had epilepsy, convulsions (but no epilepsy), 
or another condition. This was compared to the diagnosis based on cases of epilepsy identified 
by two physician billing claims or one hospital claim, resulting in a sensitivity of 89% (95% 
CI 85.4- 92.5) and specificity of 92.4% (95% CI 89.9- 94.9) (107) compared to the gold 
standard.  
Population denominator 
For the denominator, we used the supplied person registry to identify the covered 
population at the midpoint (July 1st) of each year. The denominator was stratified for various 
analyses by the calendar year (2005-2010), sex, year of birth, and RI status. Age was divided into 
eighteen groups (2-4, 5-9, 10-14,15-19, 20-24, 25-29, 30-34, 35-39, 40-44, 45-49, 50-54, 55-59, 
60-64, 65-69, 70-74-, 75-79, 80-84, 85-89 and >90). Note that information was lacking from the 
population under two years of age. 
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3.2 Analysis 
3.2.1 Descriptive statistics 
Incidence 
Incident cases were defined as those patients newly diagnosed with epilepsy between 
January 1st, 2005 and Dec 31st, 2010. Data between January 1st, 2001 and Dec 31st, 2004 was used 
as a four-year washout period as per the standards for epidemiological studies and surveillance of 
epilepsy (94) 
To measure the incidence rate (IR), we used the following formula (5): 
𝐼𝐼𝐼𝐼 = 𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁 𝑜𝑜𝑜𝑜 𝑛𝑛𝑁𝑁𝑛𝑛 𝑐𝑐𝑐𝑐𝑐𝑐𝑁𝑁𝑐𝑐 𝑜𝑜𝑜𝑜 𝑁𝑁𝑒𝑒𝑒𝑒𝑒𝑒𝑁𝑁𝑒𝑒𝑐𝑐𝑒𝑒 𝑑𝑑𝑁𝑁𝑁𝑁𝑒𝑒𝑛𝑛𝑑𝑑 𝑐𝑐 𝑑𝑑𝑒𝑒𝑔𝑔𝑁𝑁𝑛𝑛 𝑒𝑒𝑁𝑁𝑁𝑁𝑒𝑒𝑜𝑜𝑑𝑑
𝑡𝑡𝑜𝑜𝑡𝑡𝑐𝑐𝑒𝑒 person-time 𝑜𝑜𝑜𝑜 𝑜𝑜𝑁𝑁𝑐𝑐𝑁𝑁𝑁𝑁𝑔𝑔𝑐𝑐𝑡𝑡𝑒𝑒𝑜𝑜𝑛𝑛            
The numerator was the total number of new cases, which was divided by total person-time 
of observation to establish the incidence rate. Incidence was calculated for the entire observation 
period (2005 to 2010) and also calculated annually between 2005 and 2010. 
To calculate the denominator, demographers generally calculate the average number of 
people in a given year by adding the number of people at the beginning and the end of the year 
and dividing this sum by two. That is the same as the expected number of people in the middle of 
the year, assuming a linear pattern of growth (108). The concept of incidence rate in a dynamic 
population was used by William Farr in the 1850s. He explained in detail the concept of the 
dynamic population as the basis for the calculation of the rate of morbidity(108). During each year 
in a dynamic population, some people leave the province or die while other people come to live in 
the province and babies are born. This means that individuals are not the same throughout the 
whole year, yet have to be, somewhat arbitrarily, defined by a particular “state,” such as living in 
a particular province. The population  of the province therefore also varies slightly from day to 
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day and would be artificially inflated if every person in the province at any time during the year 
were counted in the total. The “perfect” denominator would, of course, involve summation of all 
the individuals time period people were present in the province (commonly called person-years), 
but this would be unwieldy. Fortunately, using the mid-year population is a good approximation 
of this sum. For example, as long as the rate of people coming and going during the year is roughly 
similar, considering one person present for four months and another present for 8 months as 
equivalent to one person present for the whole years is a reasonable approximation. Calculation of 
incidence rate base in a dynamic population is then fairly straightforward. Thus, the denominator 
(total ”person-time” of observation) in this study, was the covered Saskatchewan population as for 
July 01 for each year, excluding prevalent cases. 
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Figure 3.1 Expected number of people in a dynamic population(108) 
 
 
The 95%CI was calculated with the following formula(109):  
95%CI=𝐼𝐼𝐼𝐼 ± 1.96√𝑥𝑥/𝑇𝑇2  
IR is stated as a decimal fraction (e.g., 0.10 per person-years not 10 per 100 person-years) 
x is the number of new cases 
T is the total number of person-time units observed 
The age-standardized incidence was calculated by the direct method using the 2006 
Canadian population as the standard population. Adjustment is accomplished by first multiplying 
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the age-specific rates of disease by age-specific weights. The weights used in the age-adjustment 
of epilepsy data were the proportion of the 2006 Canadian population within each age group. The 
weighted rates are then summed across the age groups to give the age-standardized rate and was 
reported per 100,000. We followed the formula (110): 
Age-standardized rate = 𝑇𝑇𝑜𝑜𝑡𝑡𝑐𝑐𝑒𝑒 𝑁𝑁𝑒𝑒𝑒𝑒𝑁𝑁𝑐𝑐𝑡𝑡𝑁𝑁𝑑𝑑 𝑐𝑐𝑐𝑐𝑐𝑐𝑁𝑁𝑐𝑐
𝐺𝐺𝑁𝑁𝑛𝑛𝑁𝑁𝑁𝑁𝑐𝑐𝑒𝑒 𝑒𝑒𝑜𝑜𝑒𝑒𝑁𝑁𝑒𝑒𝑐𝑐𝑡𝑡𝑒𝑒𝑜𝑜𝑛𝑛 𝑁𝑁𝑐𝑐𝑡𝑡𝑁𝑁 × 100,000 
The 95% confidence interval for age-standardized rates were calculated based on a 
standard error following the formula: 
𝑆𝑆𝑆𝑆 = 𝐼𝐼/√𝑁𝑁 
where: 
R = (age-standardized) total rate 
N = number of events  
The estimated SE was then used to compute a 95% confidence interval (CI) for the rate.  
The standard formula for determining the 95% CI of a rate was(111): 
95%𝐶𝐶𝐼𝐼 = 𝐼𝐼 ± (1.96 × 𝑆𝑆𝑆𝑆) 
Prevalence 
The prevalence (P) was calculated using the following formula (5): 
𝑃𝑃 = 𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁 𝑜𝑜𝑜𝑜 𝑁𝑁𝑒𝑒𝑒𝑒𝑐𝑐𝑡𝑡𝑒𝑒𝑛𝑛𝑑𝑑 𝑐𝑐𝑐𝑐𝑐𝑐𝑁𝑁𝑐𝑐 𝑜𝑜𝑜𝑜 𝑁𝑁𝑒𝑒𝑒𝑒𝑒𝑒𝑁𝑁𝑒𝑒𝑐𝑐𝑒𝑒 𝑑𝑑𝑁𝑁𝑁𝑁𝑒𝑒𝑛𝑛𝑑𝑑 𝑐𝑐 𝑐𝑐𝑒𝑒𝑁𝑁𝑐𝑐𝑒𝑒𝑜𝑜𝑒𝑒𝑁𝑁𝑑𝑑 𝑒𝑒𝑁𝑁𝑁𝑁𝑒𝑒𝑜𝑜𝑑𝑑
𝐴𝐴𝑔𝑔𝑁𝑁𝑁𝑁𝑐𝑐𝑑𝑑𝑁𝑁 𝑒𝑒𝑜𝑜𝑒𝑒𝑁𝑁𝑒𝑒𝑐𝑐𝑡𝑡𝑒𝑒𝑜𝑜𝑛𝑛 𝑑𝑑𝑁𝑁𝑁𝑁𝑒𝑒𝑛𝑛𝑑𝑑 𝑡𝑡ℎ𝑐𝑐𝑡𝑡 𝑡𝑡𝑒𝑒𝑁𝑁𝑁𝑁 𝑒𝑒𝑁𝑁𝑁𝑁𝑒𝑒𝑜𝑜𝑑𝑑 × 1,000            
The numerator was the number of existing alive cases of epilepsy each year for 2005 to 
2010. The denominator was the average covered population on July 01 of each specific year. 
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The 95% confidence intervals for prevalence was calculated using  the score method with 
the following formula (109): 
95%CI= 𝑝𝑝 ±  1.96 (√𝑝𝑝 (1 − 𝑝𝑝))/(𝑛𝑛 + 4)) 
where p = (x + 2)/(n + 4)  
p refers to the standardized sample proportion (prevalence stated as a decimal fraction)  
n is the appropriate denominator 
x is the appropriate numerator  
The prevalence was age-standardized by the direct method using the 2006 total Canadian 
population as standard population using the above formula(110). 
The 95% confidence interval for age-standardized prevalence was calculated based on a 
standard error (111). 
Mortality 
The Standardized Mortality Ratio (SMR) was calculated with indirect standardization 
formula(110): 
𝑆𝑆𝑆𝑆𝐼𝐼 = 𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂 𝑛𝑛𝑛𝑛𝑛𝑛𝑂𝑂𝑂𝑂𝑂𝑂 𝑜𝑜𝑜𝑜 𝑂𝑂𝑂𝑂𝑑𝑑𝑑𝑑ℎ𝑂𝑂
𝑆𝑆𝑥𝑥𝑝𝑝𝑂𝑂𝐸𝐸𝑑𝑑𝑂𝑂𝑂𝑂 𝑛𝑛𝑛𝑛𝑛𝑛𝑂𝑂𝑂𝑂𝑂𝑂 𝑜𝑜𝑜𝑜 𝑂𝑂𝑂𝑂𝑑𝑑𝑑𝑑ℎ𝑂𝑂  
The all-cause mortality of patients with epilepsy was calculated for the six-year interval 
2005 to 2010, and for each calendar year. The unit of study was person-years. For each age group, 
we computed mortality rates for persons in the general population (Saskatchewan Population) 
based on specific mortality data of the province from Statistics Canada. These rates were then 
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applied to the age- and sex-specific exposure times for persons in the study with a diagnosis of 
epilepsy. This yielded an expected number of deaths. The ratio of observed to expected number of 
deaths was the standardized mortality ratio (SMR).  
The 95% confidence interval (95% CI) of the SMR was calculated, assuming a Poisson 
distribution for the observed number of deaths following the formula (112): 
Lower:  𝑂𝑂
𝐸𝐸
�1 − 1
9  𝑒𝑒 𝑂𝑂 − 1.963 √𝑂𝑂�3 
Upper:  𝑂𝑂+1
𝐸𝐸
�1 −  1
9 ( 𝑂𝑂+1 + 1.963√𝑂𝑂+1�3 
O refers to the observed mortality rate 
E refers to the expected mortality rate 
A p-value of <0.05 was considered to be statistically significant for all the analysis. 
3.2.2 Statistical Inference  
For incidence and prevalence, we calculated the changes between 2005 and 2010 in 
absolute numbers. For a measure of association between incidence rate of epilepsy for sex, and RI 
status we calculated the rate ratio (RR). The rate ratio (RR) was calculated to measure contributions 
to the incidence of epilepsy due to demographic characteristics (male, and RI status, and  the 
difference in time) using the following formula (113):  
𝐼𝐼𝐼𝐼 = 𝐼𝐼𝐼𝐼 (𝑤𝑤𝑤𝑤𝑑𝑑ℎ 𝑂𝑂𝑂𝑂𝑛𝑛𝑜𝑜𝑑𝑑𝑂𝑂𝑑𝑑𝑝𝑝ℎ𝑤𝑤𝐸𝐸 𝐸𝐸ℎ𝑑𝑑𝑂𝑂𝑑𝑑𝐸𝐸𝑑𝑑𝑂𝑂𝑂𝑂𝑤𝑤𝑂𝑂𝑑𝑑𝑤𝑤𝐸𝐸𝑂𝑂 𝐼𝐼𝐼𝐼 (𝑛𝑛𝑜𝑜𝑛𝑛 − 𝑂𝑂𝑂𝑂𝑛𝑛𝑜𝑜𝑑𝑑𝑂𝑂𝑑𝑑𝑝𝑝ℎ𝑤𝑤𝐸𝐸 𝐸𝐸ℎ𝑑𝑑𝑂𝑂𝑑𝑑𝐸𝐸𝑑𝑑𝑂𝑂𝑂𝑂𝑤𝑤𝑂𝑂𝑑𝑑𝑤𝑤𝐸𝐸𝑂𝑂⁄  
We explored significant changes (p < 0.05) using X2 test, and 95% confidence intervals 
(95%CI). 
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The prevalence ratio (PR) was used for measures of association between two prevalences, 
calculated with the following formula (114): 
PR=prevalence D /prevalence O 
where prevalence (D) = a/(a+b) (a= cases of the disease with the demographic characteristic 
and b= cases free of disease with the demographic characteristics 
prevalence O = c/ (c+d) (c=cases of the disease without the demographic characteristic and 
d=cases free of disease without the demographic characteristic) 
We tested for significant changes (p <0.05) using X2 test and 95% confidence intervals 
(95%CI)(113).  
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CHAPTER 4: RESULTS 
4.1 Incidence of epilepsy in Saskatchewan 
 4.1.1 Overall incidence of epilepsy in general population 
Analysis of our Ministry of Health (Saskatchewan, Canada) data files revealed a total of 
6,060,356 person-years of follow-up in Saskatchewan, Canada, for the development of epilepsy 
between 2005 and 2010. A total of 3,804 new epilepsy patients were found, giving a crude overall 
incidence rate of 62.8 per 100,000 person-years (95%CI = 60.8, 64.8) and the age-standardized 
(for the 2006 Canadian population) incidence of 61.98 per 100,000 person-years (95% CI= 60.0, 
63.9). The cases included 2025 (53.2%) male patients and 1779 (46.8%) female patients. Age-
standardized incidences were 66.8 (95%CI: 63.9, 69.7) for male patients and 57.1 (95%CI: 54.5, 
59.8) for female patients (Table 4.1). 
4.1.2 Age-specific incidence of epilepsy in the general population  
Using cumulative data from 2005-2010, we found fluctuations in epilepsy incidences 
within the younger age groups but an increasing incidence toward a high point in the75-79 age 
group (133.5/100,000 person-years) (Table 4.2). The age-specific incidence was similar in males 
and females in the 5-39 year group. In individuals older than 39 years, the incidence in men was 
consistently higher than women (Figure 4.1). 
4.1.3 Temporal changes of incidence in the general population 
 As shown in Figure 4.2, there was a decreasing trend over time in the age-standardized 
incidence of epilepsy. From 2005 to 2010, the annual incidence of epilepsy decreased from 
69.5/100,000 in 2005 to 43.9/100,000 in 2010 (RR = 0.63; 95% CI 0.56–0.71, p < 0.0001) (Table 
4.3). 
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A significant decrease in incidence between beginning and the end of the study period 
occurred in both men (from 72.4/100,000 to 48.6/100,000; RR: 0.67; 0.57–0.78, p = <0.0001) and 
women (from 66.5/100,000 to 39.2/100,000; RR: 0.59; 0.49–0.70, p = <0.0001) (Table 4.3 and 
Figure 4.2) 
4.1.4 Incidence of epilepsy in self-declared Registered Indians (RI)  
In the RI group there were 608 patients with a diagnosis of new-onset epilepsy over the 
cumulative period 2005-2010 with 639,972 person-years of follow-up, resulting in a crude 
incidence of epilepsy in this group of 95 per 100,000 person-years (95%CI: 87.4, 102.6) and age-
standardized incidence of 121.9 per 100,000 person-years (95%CI: 112.2, 131.6). The age-
standardized incidence in males was 140.4 per 100,000 person-years (95%CI: 125.2, 154.5) and 
the incidence in females was 104.7 (95%CI: 92.4, 116.7). 
4.1.4.1 Differences in the incidence of epilepsy between Registered Indians vs. not 
Registered Indians 
The age-standardized incidence of epilepsy for RI compared with non-RI is shown in Table 
4.4. This shows an overall (male and females together) rate ratio of 1.62 (95% CI: 1.49, 1.77) for 
the incidence of epilepsy among RI compared with non-RI.  In other words, people who ever self-
identified as RI were approximately 1.62 times more likely (p=<0.001) to be newly diagnosed with 
epilepsy than people who never self-identified as RI in Saskatchewan. These differences were 
statistically significant in both sexes. RI males were 1.66 (95% CI 1.47, 1.86) more likely to be 
newly diagnosed with epilepsy than non-RI males.  
Similarly, RI females were 1.58 times (95% CI= 1.39, 1.80) more likely to be newly- 
diagnosed with epilepsy than non- RI females. 
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The age-specific distribution of epilepsy among RI compared to non-RI in Saskatchewan 
between 2005 and 2010 showed that from the 15-19 age group to the 65-69 age group, the 
incidence of epilepsy was significantly higher (p=<0.05) among RI compared to non-RI, with the 
highest rate ratio of 4.52 (95%CI= 3.39, 6.05) in the 45-49 age group (Table 4.5 Comparison of 
age-specific incidence of epilepsy per 100,000 person-years between Registered Indians vs. non-
Registered Indians for the period of 2005-2010 and Figure 4.3). 
4.1.4.2 Age-specific incidence of epilepsy in self-declared Registered Indians 
Over the cumulative period of 2005-2010, the incidence of epilepsy in RI varied by age 
group (Table 4.6 and Figure 4.3). The highest incidence was the 55-59 age group at 216.4 per 
100,000 person-years (95%CI: 146.7, 286.2) and lowest (zero incidences) in the 80-84 group age.  
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Table 4.1 Crude and age-standardized incidence of epilepsy in Saskatchewan, Canada by year and sex for the period 2005-2010 
 2005 2006 2007 2008 2009 2010 2005-2010 
Person per years 
population 
Males 
Females 
Overall 
 
 
 
497111 
503413 
1000524 
 
 
489006 
497018 
986024 
 
 
494314 
500735 
995049 
 
 
505500 
509700 
1015200 
 
 
507392 
512668 
1020060 
 
 
520422 
523077 
1043499 
 
 
3127425 
3143868 
6271293 
Incidence cases 
Males 
Females 
Overall 
 
 
360 
335 
695 
 
429 
357 
786 
 
344 
283 
627 
 
351 
305 
656 
 
291 
308 
599 
 
253 
205 
458 
 
2025 
1779 
3804 
Crude incidence 
per 100,000 
(95%CI) 
     Male 
Female 
Overall 
 
 
 
 
 
72.4 (64.9,79.9) 
66.5 (59.4, 73.7) 
69.5 (64.3, 74.6) 
 
 
 
87.7 (79.4, 96.0) 
71.8(64.4, 79.3) 
79.7(74.1, 85.3) 
 
 
 
69.6(62.2, 76.7) 
56.5(53.1, 66.5) 
64.0(59.7, 69.6) 
 
 
 
69.4(62.5, 77.2) 
59.8(52.1, 67.7) 
64.6 (60.6, 70.8) 
 
 
 
57.35 (50.8, 63.9) 
60.08(53.4, 66.8) 
58.72(54.0, 63.4) 
 
 
 
48.6(42.6, 54.6) 
39.2 (33.8, 44.6) 
43.9(39.9, 47.9) 
 
 
 
67.19(64.3,70.1) 
58.39(55.7,61.1) 
62.77(60.8,64.8) 
Age-standardized 
incidence  
per 100,000ƻ 
(95%CI) ƻ 
Male 
Female  
Overall 
 
 
 
 
 
 
 
72.0(64.6, 79.5) 
64.8(57.9, 71.8) 
 68.1(63.3, 73.5) 
 
 
 
 
 
86.9 (75.7,91.6) 
69.9 (61.2, 75.3) 
78.4 (72.5, 83.4) 
 
 
 
 
 
 
69.1(61.9, 76.4)  
58.4(51.9, 65) 
63.8(58.9, 68.7) 
 
 
 
 
 
 
69.9(62.6, 77.2) 
58.9(52.3, 65.5)  
65.7(60.7, 70.7) 
 
 
 
 
 
56.8(50.2, 63.3) 
58.8(52.2,65.3) 
57.8(53.1, 62.4) 
 
 
 
 
 
48.0(42.1, 54) 
38.4(33.2, 43.7) 
43.3(39.3, 47.5) 
 
 
 
 
 
 
66.8(63.9,69.7) 
57.1(54.46,59.8) 
62(60,63.9) 
 
ƻ Standardized for the 2006 Canadian Population 
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Table 4.2 Age-specific incidence of epilepsy per 100,000 person-years in Saskatchewan, Canada, for the cumulative period of 2005-
2010 
Age group 
(years) New cases Average Population 
Crude prevalence 
Per 1,000 
95% CI 
 
Lower Upper 
Overall 
2-4 
5 to 9 
10 to 14 
15-19 
20-24 
25-29 
30-34 
35-39 
40-44 
45-49 
50-54 
55-59 
60-64 
65-69 
70-74 
75-79 
80-84 
85-89 
Total 
 
119 
185 
169 
286 
224 
185 
182 
216 
204 
283 
299 
263 
218 
203 
211 
220 
180 
157 
3804 
 
228213 
377709 
410366 
461158 
465705 
425800 
386438 
374422 
414987 
471302 
451319 
377696 
297866 
232099 
200895 
180566 
171492 
132323 
6060356 
 
52.1 
49.0 
41.2 
62.0 
48.1 
43.4 
47.1 
57.7 
49.2 
60.0 
66.2 
69.6 
73.2 
87.5 
105.0 
121.8 
105 
118.6 
62.8 
 
42.8 61.5 
41.9 56.0 
35.0 47.4 
55.0 69.2 
41.8 54.4 
37.2 49.7 
40.2 53.9 
50.0 65.4 
42.4 55.9 
53.0 67.0 
58.7 73.8 
61.2 78.0 
63.5 82.9 
75.4 99.5 
90.9 119.2 
105.7 137.9 
89.6 120.3 
100.1 137.2 
60.8 64.8 
 
95%CI= 95% confidence intervals 
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Figure 4.1 Age-specific incidence of epilepsy by gender in Saskatchewan, Canada, 2005-2010 
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Figure 4.2 Age-standardized incidence of epilepsy in Saskatchewan, Canada, 2005-2010 
 
Age-standardized to the 2006 Canadian census population 
  
0.00
10.00
20.00
30.00
40.00
50.00
60.00
70.00
80.00
90.00
2 0 0 5 2 0 0 6 2 0 0 7 2 0 0 8 2 0 0 9 2 0 1 0
In
ci
de
nc
e 
pe
r 1
00
,0
00
 p
er
so
n-
ye
ar
CALENDAR YEAR
Overall Male Female
  
 
 37 
 
Table 4.3 Changes in the incidence of epilepsy by sex in Saskatchewan, Canada, between 2005 and 2010 
 2005 2010 Changes between 2005 and 2010 
 
n % 
Crude rate per 
100,000 
person-years(CI) 
Age-standardized 
rate per 100,000 
person-years(CI) 
n % 
Crude rate 
per 100,000 
person-
year(CI) 
Age-standardized 
rate per 100,000 
person-years(CI) 
n % 
change 
Rate 
ratio CI p 
Male 
 
360 
 
51.8 
 
72.4 (64.9,79.9) 
 
72(64.6, 79.5) 
 
253 
 
55.24 
 
48.6(42.6, 54.6) 
 
48.0(42.1, 54) 
 
107 
 
-30.5 
 
0.67 
 
0.57, 0.78 
 
<0.001 
 
Female 
 
335 48.2 66.5 (59.4, 73.7) 64.8(57.9, 71.8) 205 44.76 39.2 (33.8,44.6) 38.4(33.2, 43.7) 130 -40.5 0.59 0.49, 0.70 <0.001 
Overal
l 695 - 69.5 (64.3, 74.6) 68.4(63.3, 73.5) 458 - 43.9(39.9, 47.9) 43.3(39.3, 47.2) 237 -34.7 0.63 0.56,0.71 <0.001 
              
ƻ Standardized for the 2006 Canadian Population 
95% CI=Confidence interval; RR= rate ratio; p significant= < 0.05 
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Table 4.4 Comparison of age-standardized incidence of epilepsy per 100,000 person-years between Registered Indians vs. non-
Registered Indians for the cumulative period of 2005-2010 
 Ever self-identified RI Never self-Identified RI 
Rate 
ratio 95% CI p 
 Age-standardized 
incidence per 
100,000 person-
years 
95% CI 
Age-standardized 
incidence per 
100,000 person-
years 
95%CI 
 
Male 
 
140.4 
 
125.2, 154.5 
 
51.4 
 
48.7, 54.0 
 
1.66 
 
1.47,1.86 
 
<0.001 
Female 104.7 92.5, 116.7 46.2 43.7, 48.7 1.58 1.39, 1.80 <0.001 
Overall 121.9 112.2, 131.6 48.8 47.0, 50.6 1.62 1.49,1.77 <0.001 
        
Age-standardized to the 2006 Canadian census population, 95%CI= confidence intervals; significant p= <0.05 
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Table 4.5 Comparison of age-specific incidence of epilepsy per 100,000 person-years between Registered Indians vs. non-Registered 
Indians for the period of 2005-2010 
 Ever self-identified RI Never self-identified as RI 
Rate 
ratio 
95% 
 CI p Age group 
New 
cases 
Person per- 
years 
population 
Crude 
rate 
95% 
 CI 
New 
cases 
Person 
per-year 
population 
Crude 
rate 
95% 
CI 
 
2-4 
5-9 
10-14 
15-19 
20-24 
25-29 
30-34 
35-39 
40-44 
45-49 
50-54 
55-59 
60-64 
65-69 
70-74 
75-79 
80-84 
85-89 
Total 
 
 
34 
42 
37 
61 
43 
41 
48 
60 
58 
61 
34 
37 
20 
16 
8 
7 
1 
0 
  608 
 
53164 
81705 
77683 
76868 
63760 
51078 
45378 
43915 
39651 
32682 
24182 
17096 
11902 
8135 
5620 
3712 
2199 
1242 
639972 
 
63.9 
51.4 
47.6 
79.4 
67.4 
80.3 
105.8 
136.6 
146.3 
186.6 
140.6 
216.4 
168.0 
196.7 
142.3 
188.6 
45.5 
0.00 
95.0 
 
42.5, 85.4 
35.9, 66.9 
32.3, 63.0 
59.4, 99.3 
47.3, 87.6 
55.7, 104.8 
75.8, 135.7 
102.1, 171.2 
108.6, 183.9 
139.8, 233.5 
93.3, 187.9 
146.7, 286.2 
94.4, 241.7 
100.3, 293.0 
43.7, 241.0 
48.9, 328.3 
-43.7, 134.6 
0.00 
87.4, 102.6 
 
80 
116 
119 
196 
153 
121 
105 
144 
123 
181 
231 
191 
177 
152 
197 
171 
153 
134 
2744 
 
175049 
296004 
332683 
384290 
401945 
374722 
341060 
330507 
375336 
438620 
427137 
360600 
285964 
223964 
195275 
176854 
169293 
131049 
5420352 
 
45.7 
39.2 
35.8 
51.0 
38.1 
32.3 
30.8 
43.6 
32.8 
41.3 
54.1 
53.0 
61.9 
67.9 
100.9 
96.7 
90.4 
102.2 
50.6 
 
35.7, 55.7 
32.1, 46.3 
29.3, 42.2 
43.9, 58.1 
32.0, 44.1 
26.5, 38.0 
24.9, 36.7 
36.4, 50.7 
27.0, 38.6 
35.2, 47.3 
47.1, 61.1 
45.5, 60.5 
52.8, 71.0 
57.1, 78.7 
86.8, 115.0 
82.2, 111.2 
76.1, 104.7 
84.9, 119.6 
48.7, 52.5 
 
1.49 
1.31 
1.33 
1.55 
1.77 
2.48 
3.43 
3.13 
4.46 
4.52 
2.60 
4.08 
2.71 
2.89 
1.41 
1.95 
0.50 
0.00 
1.87 
 
0.93, 2.08 
0.92, 1.86 
0.92, 1.92 
1.17,2.07 
1.26,2.48 
1.74,3.54 
2.44,4.83 
2.32, 4.24 
3.27, 6.10 
3.39,6.05 
1.81, 3.72 
2.87, 5.81 
1.71, 4.31 
1.73,4.85 
0.69, 2.86 
0.92, 4.15 
0.07, 3.59 
0.00, 2.38 
1.72, 2.05 
 
 
0.10 
0.14 
0.13 
0.003 
0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
0.33 
0.11 
0.55 
0.28 
<0.001 
95% CI= 95% Confidence interval; RR= rate ratio; p significant= < 0.05 
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Figure 4.3 Age-specific incidence of epilepsy by Registered Indian status in Saskatchewan, Canada, 2005-2010 
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4.2 Prevalence of epilepsy in Saskatchewan 
4.2.1 Overall prevalence in the general population 
The total number of people in Saskatchewan, Canada, living with epilepsy in 2010 was 
8,880, representing a crude prevalence of 8.5 per 1,000 people (95%CI=8.3, 8.7). After adjustment 
to the Canadian population in 2006, the prevalence of epilepsy in Saskatchewan was 8.8 per 1,000 
people (95%CI= 8.6, 9.0). The prevalent cases included 4,635 (52.2%) males and 4,245 (47.8%) 
females, resulting in age-standardized prevalence of 9.2 per 1,000 people (95%CI=8.9, 9.4) in 
males and 8.4 per 1,000 people (95%CI=8.5, 8.7) in females. (Table 4.6) 
4.2.2 Age-specific prevalence in the general population 
Table 4.7 and Figure 4.4 show the age-specific prevalence of epilepsy in Saskatchewan for 
2010. There was a trimodal pattern in the overall age-specific epilepsy prevalence with peaks in 
the 15-19 age group (8.7 per 1,000 people; 95% CI 8.0, 9.4), the 35-39 age group (12.5 per 1,000 
people; 95%CI=11.6, 13.4) and then a slow rise towards the 80-84 age group (11.9 per 1,000 
people; 95%CI= 10.6, 13.3). 
4.2.3 Temporal trends in the prevalence of epilepsy in the general population 
Over the six-year study period (2005-2010), the overall midyear population decreased from 
1,046,964 to 1,043,467 (Figure 4.5). However, the absolute number of overall prevalent cases of 
epilepsy increased each year from 6,637in 2005 to 8,800 in 2010 (see Table 4.6) resulting in a 
significant increase (p=<0.001) in the age-standardized prevalence from 6.6 in 2005 (95%CI=6.2, 
6.5) to 8.8 per 1,000 people in 2010 (95%CI=8.6, 9.0) (Table 4.8). 
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Table 4.6 Annual prevalence of epilepsy per 1,000 people in Saskatchewan 
 
ƻ Standardized for the 2006 Canadian Population 
  
 2005 2006 2007 2008 2009 2010 
Midyear population  
Males 
Females 
Overall 
 
 
522085 
524879 
1046964 
 
489006 
497018 
986024 
 
494314 
500735 
995049 
 
505500 
509700 
1015200 
 
507392 
512668 
1020060 
 
520390 
523077 
1043467 
Prevalence cases 
Males  
Females 
Overall 
 
 
3463 
3174 
6637 
 
3704 
3422 
7126 
 
4016 
3673 
7689 
 
4242 
3860 
8102 
 
4474 
4058 
8532 
 
4635 
4245 
8880 
Crude prevalence per 
1,000 people (95%CI)  
      Male 
Female 
Overall 
 
 
 
 
6.6(6.4, 6.8) 
6.0 (5.8, 6.3) 
6.3(6.2, 6.5) 
 
 
 
 
7.6(7.3, 7.8) 
6.9(6.7, 7.1) 
7.2(7.1, 7.4) 
 
 
 
 
8.0(7.7, 8.2) 
7.2(6.9, 7.4) 
7.7(7.6, 7.9) 
 
 
 
 
8.4(8.1, 8.6) 
7.5(7.3, 7.8) 
8.0(7.8, 8.2) 
 
 
 
 
8.7(8.5, 9.0) 
7.9(7.6, 8.1) 
8.4(8.2, 8.5) 
 
 
 
 
8.9 (8.7, 9.2) 
8.1(7.9, 8.4) 
8.5(8.3, 8.7) 
 
% of change 
between each year 
 
 
14% 
 
6.9% 
 
3.2% 
 
4.7% 
 
0.7% 
 
Age-standardized 
prevalence per 1,000 
(95%CI)ƻ 
Male 
Female  
Overall 
 
 
 
 
 
6.8 (6.6, 7.1) 
6.3 (6.1, 6.5) 
 6.6 (6.4, 6.7) 
 
 
 
7.7 (7.5, 8.0) 
7.1 (6.9, 7.4) 
 7.4(7.3, 7.6) 
 
 
 
 
8.3(8.0, 8.6)  
7.6(7.3, 7.8) 
 7.9(7.8, 8.1) 
 
 
 
 
8.6(8.3, 8.8) 
7.8(7.6, 8.1) 
8.2(8.0, 8.4) 
 
 
 
9.0(8.8, 9.3) 
8.2(7.9, 8.4) 
8.6(8.4, 8.8) 
 
 
 
9.2(8.9, 9.4) 
8.4(8.1, 8.7) 
8.8(8.6, 9.0) 
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Figure 4.4 Age-specific prevalence of epilepsy in Saskatchewan, 2010 
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Table 4.7 Age-specific prevalence of epilepsy per 1,000 people in Saskatchewan, Canada, for 2010 
Age group 
(years) 
Identified 
cases Midyear population 
Crude prevalence 
Per 1,000 people 
95% CI 
 
Lower Upper 
Overall 
2-4 
5 to 9 
10 to 14 
15-19 
20-24 
25-29 
30-34 
35-39 
40-44 
45-49 
50-54 
55-59 
60-64 
65-69 
70-74 
75-79 
80-84 
85-89 
Total 
 
246 
417 
397 
646 
662 
576 
615 
813 
742 
783 
669 
507 
430 
398 
357 
332 
290 
0 
8880 
 
41936 
64674 
66674 
74462 
79569 
77070 
70184 
65185 
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Figure 4.5 Annual age-standardized prevalence of epilepsy in Saskatchewan, Canada, 2005-2010 
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Table 4.8 Changes in the prevalence of epilepsy in Saskatchewan, Canada, between 2005 and 2010 
 2005 2010 Changes between 2005 and 2010 
 
Existent cases % 
Crude rate 
per 1,000 
People(CI) 
Age-
adjusted 
rate per 
1,000 
people(CI) 
Existent 
cases % 
Crude rate 
per 1,000 
people(CI) 
Age-adjusted 
rate per 1,000 
people(CI) 
n % PR 95%CI p 
Male 3463 52.2 6.6(6.4, 6.9) 6.8 (6.6, 7.1) 4635 52.2 8.9(8.7, 9.2) 9.2(8.9, 9.4) 1172 0 1.34 1.28, 1.40 <0.001 
Female 
 3174 47.8 6.0(5.8, 6.3) 6.3 (6.1, 6.5) 4245 47.8 8.1(7.9, 8.4) 8.4(8.1, 8.7) 1071 0 1.34 1.28, 1.40 <0.001 
Overall 
 6637 ----- 6.3(6.2, 6.5) 6.6 (6.4, 6.7) 8880 ---- 8.5(8.3, 8.7) 8.8(8.6, 9.0) 2243  1.34 1.30, 1.38 <0.001 
n= number of existent cases, %= percentage, CI= 95% confidence intervals; p= <0.05; PR= prevalence ratio 
Age-adjusted to the 2006 Canadian population. 
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4.3 Mortality of epilepsy in Saskatchewan 
4.3.1 Overall all-cause mortality  
SMRs and specific death rates for epilepsy were calculated cumulatively (period 2005-
2010) as well as annually. A total of 1470 deaths (816 in males and 654 in females) occurred 
during 6,307,668 person-years follow-up period (2005-2010) in patients with epilepsy. During the 
same period, 76,122 people died from all causes in the general population of Saskatchewan 
resulting in an expected number of 599.94 deaths (expected number = mortality rate in the general 
population of Saskatchewan times number of people with epilepsy). The overall all-cause SMR 
for epilepsy based on the study group was therefore 2.45 (95%CI 2.33, 2.58) (observed number of 
deaths/ expected number of deaths: 1470/599.94) (Table 4.9). 
By sex, the SMR was 2.66 (95%CI 2.48, 2.85) for male, and 2.24 (95%CI 2.07, 2.42) for 
females.  
4.3.2 Age-specific all causes of mortality  
Analysis of age-specific mortality rates (Table 4.9) revealed significantly higher SMR in 
people with epilepsy in all age groups. The highest overall SMR was observed in children in the 
5-9 age groups (SMR 19.68; 95% CI=6.25, 30.27) and the 10-14 years age groups (SMR 22.6; 
95% CI=8.75, 40.07). The lowest SMR was found in 2-4 years group (SMR: 1.40: 95%CI 0.10, 
3.37) and the 75-79 age group (SMR 1.89; 95% CI= 1.64, 2.14) (see Figure 4.6) 
4.3.3 SMR temporal trends for all causes of mortality  
Over the six-year period of the study, the SMR for both sexes together remained fairly 
constant, but sex-specific rates showed some fluctuation over the years, as shown in Figure 4.7.
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Table 4.9 Cumulative age-specific distribution of Standardized Mortality ratios of all-cause mortality among patients with epilepsy vs. 
the general population in Saskatchewan, Canada, for the period 2005-2010 
No. of deaths 
  Male Female Overall 
 Obs Exp SMR 
95% CI 
Obs Exp SMR 
95%CI 
Obs Exp SMR 
95%CI 
Lower Upper lower upper lower Upper 
Overall 816 307.14 2.66 2.48, 2.85 654 292.30 2.24 2.07, 2.42 1470 599.94 2.45 2.33           2.58 
Age 
group(y) 
2-4 
5 to 9 
10 to 14 
15-19 
20-24 
25-29 
30-34 
35-39 
40-44 
45-49 
50-54 
55-59 
60-64 
65-69 
70-74 
75-79 
80-84 
85 to 89 
 
 
1 
3 
5 
4 
5 
14 
15 
23 
33 
44 
64 
72 
56 
59 
88 
79 
115 
136 
 
 
1.21 
0.19 
0.21 
1.97 
2.19 
1.69 
1.90 
3.45 
5.87 
7.53 
8.58 
9.06 
13.24 
21.45 
28.59 
45.14 
58.99 
0.00 
 
 
0.83 
15.75 
23.34 
2.03 
2.28 
8.29 
7.88 
6.66 
5.62 
5.84 
7.46 
7.95 
4.23 
2.75 
3.08 
1.75 
1.95 
0.00 
 
 
0.01, 4.59 
3.17, 46.02 
7.52, 54.48 
0.55, 5.19 
0.73, 5.32 
4.53, 13.91 
4.41, 13.01 
4.22, 10.00 
3.87, 7.89 
4.25, 7.84 
5.75, 9.53 
6.22, 10.01 
3.19, 5.49 
2.09, 3.55 
2.47, 3.79 
1.39, 2.18 
1.61, 2.34 
 
 
 
1 
3 
3 
3 
8 
4 
9 
18 
21 
26 
43 
41 
36 
43 
41 
83 
106 
165 
 
 
0.94 
0.16 
0.18 
0.86 
1.02 
0.78 
1.17 
1.90 
2.81 
3.87 
5.20 
5.45 
6.28 
10.77 
18.50 
29.80 
57.67 
0.00 
 
 
1.07 
18.72 
16.80 
3.50 
7.82 
5.11 
7.67 
9.49 
7.46 
6.72 
8.27 
7.52 
5.73 
3.99 
2.22 
2.78 
1.84 
0.00 
 
 
0.01, 5.94 
3.76, 54.68 
3.38, 49.10 
0.70, 10.22 
3.37, 15.40 
1.37, 13.07 
3.50, 14.57 
5.62, 15.00 
4.62, 11.41 
4.39, 9.85 
5.98, 11.14 
5.40, 10.20 
4.02, 7.94 
2.89, 5.38 
1.59, 3.01 
2.22, 3.45 
1.50, 2.22 
 
 
 
2 
6 
8 
7 
13 
18 
24 
41 
54 
70 
107 
113 
92 
102 
129 
162 
221 
301 
 
 
2.14 
0.35 
0.39 
2.79 
3.20 
2.46 
3.09 
5.33 
8.47 
11.16 
13.68 
14.42 
19.06 
31.33 
46.75 
73.93 
117.68 
0.00 
 
 
1.40 
19.68 
22.60 
2.84 
4.35 
7.67 
8.05 
7.86 
6.48 
6.35 
7.89 
7.90 
4.87 
3.28 
2.78 
2.20 
1.89 
0.00 
 
 
0.10 
6.25 
8.75 
1.00 
2.16 
4.33 
4.97 
5.52 
4.79 
4.89 
6.41 
6.46 
3.89 
2.65 
2.30 
1.87 
1.64 
 
 
 
3.37 
37.27 
40.07 
5.16 
6.95 
11.54 
11.54 
10.44 
8.32 
7.92 
9.45 
9.42 
5.92 
3.95 
3.28 
2.56 
2.14 
 
95%CI = 95% confidence interval; Exp = expected; Obs = observed; SMR = standardized mortality ratio 
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Figure 4.6 Age-specific Standardized Mortality Ratio for epilepsy in Saskatchewan, Canada, 2005-2010 
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Figure 4.7 Annual Standardized Mortality Ratio (SMR) for epilepsy in Saskatchewan, Canada, 2005-2010 
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CHAPTER 5: DISCUSSION, CONCLUSIONS, AND RECOMMENDATIONS 
5.1 Discussion 
5.1.1 Incidence  
Population-based incidence studies of epilepsy are scarce in Canada. The present study 
measured the incidence of epilepsy in the general Canadian population without limiting the 
analysis by demographic characteristics (male, and RI status, and  the difference in time). This 
study is also the first one in Canada to measure the incidence of epilepsy in specific subgroups and 
calculate their standardized mortality ratios. Furthermore, this study examined temporal changes 
in the incidence, prevalence, and mortality of epilepsy using longitudinal data, thus maximizing 
the sensitivity of identifying PWE over time. 
5.1.1.1 Overall incidence of epilepsy 
The crude and age-standardized to the 2006 Canadian population incidence rates of 
epilepsy in Saskatchewan, Canada were estimated to be  63 and 62 cases per 100,000 person-years 
respectively and were consistent with other total population studies in developed countries (range 
40-70 per 100 000 person-years) (18,19).  
5.1.1.2 Sex and age-specific incidence rate of epilepsy  
We found a slightly higher incidence of epilepsy for men than for women. Similar 
variations by sex have also been found in other studies in developed countries (39, 40). The reasons 
behind these gender differences are not clear. One possible explanation is the higher rate of 
concussions among males between 16 and 34 years of age than females (115). In epilepsy, head 
injuries account for 20% of symptomatic epilepsy in the general population and 5% of all 
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epilepsy(116). The higher rate of concussions among males might explain the slightly higher 
incidence of epilepsy in this group compared to females. 
Another factor that may contribute to the differences in the incidence of epilepsy between 
sexes is the higher prevalence in boys of almost all developmental disabilities (DD) (117). Some 
male predominant causes of DD,  such as Fragile X Syndrome, have long been recognized, and 
are known to be associated with a higher prevalence of epilepsy (118). Other X-linked disorders 
resulting in intellectual disability have more recently been described (119), as advances in the field 
of genetics have accelerated.  In many of the other causes of DD, the male preponderance is still 
not well understood etiologically. However, regardless of the reasons for a male preponderance in 
children with DD, high rates of epilepsy in DD would then naturally be expected to result in higher 
rates of epilepsy in males than females overall.  In fact, systematic reviews have clearly established 
epilepsy to be the most prevalent condition  (22.0 in 100) in children with DD(120), especially 
those with greater severity of DD. Unfortunately, patients with DD are also more likely to have 
hard to treat (drug-resistant) epilepsy (121–123), so their need for access to specialty epilepsy 
clinics is often considerable. 
On the other hand, we corroborated previous findings of a low incidence rate in adulthood 
compared to the elderly population (36). In the pediatric population, we did not have data for 
patients under two years due to the diagnosis algorithm excluding this population. However, in the 
age group between 2 and 14 years, the incidence of epilepsy (47.7 and 42.2 per 100,000 person-
years) was close to the incidence described previously in the pediatric Canadian population (46 
per 100,000)(13). 
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5.1.1.3 Temporal changes in the incidence  
There are few studies reporting incidence rates for more than one time period with the same 
method of case ascertainment(124). In this study, we calculated the incidence of epilepsy over six-
year period in the same population with the same method of case ascertainment for the first time 
in Canada. 
In this study, we found a significant decrease in the incidence of epilepsy over the study 
period. This decreased incidence has been seen previously in Iceland (38), Finland (125) and 
UK(53) where better perinatal and neonatal care , universal vaccination, a method of ascertainment 
for the diagnosis of epilepsy(drug use database), have been thought to account for this decrease 
(126–128).  
It is difficult to attribute the decrease of epilepsy in our population to one cause alone. 
Epilepsy is a condition with many possible causes. Anything that disturbs the normal pattern of 
neuronal activity in the brain such as abnormal brain development, illness or trauma can lead to 
seizures (129). There are some public health measures which may prevent new cases of epilepsy 
in the population. They include 1) good prenatal and postnatal care related to pregnancy and 
postnatal care;  2) the prevention of head injury and other trauma: wearing seatbelts, use of bicycle 
helmets, the use of car seats for infants; 3) treating cardiovascular disease: adequate management 
of high blood pressure; and 4) preventing and treating effectively infection that may affect the 
brain during childhood and adulthood (130).  
It is interesting that countries, where the incidence of epilepsy has decreased have a 
universal health care publicly funded system, unlike countries where the incidence of epilepsy has 
increased such as in the USA (36). The presence of universal health care may have led to better 
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public health, resulting in the reduction of diseases, healthier people, and  ultimately a decrease in 
the incidence of epilepsy(131).  
Another cause of  the decreased incidence of epilepsy could have been the immigration of 
healthy people in those aged 20-59 (5,132) where the decreased incidence of epilepsy in 
Saskatchewan was noted. The migration of healthy immigrants has been well documented in 
Hispanic and Latino American immigrants in the U.S. where these groups tend to have comparable 
to or better health outcomes than those of their non-Hispanic, white counterparts(133). Information 
from Statistics Canada shows that the percentage of landed immigrants in Saskatchewan increased 
from 0.8% in 2005 (Canada 100%) to 2.7% in 2010(134). Within the 2006 Canadian census there 
were 48,155 immigrants in Saskatchewan, and in 2012, the interprovincial migration together with 
the increase in immigration added 80,000 people to the province(135). Furthermore, 58.6% people 
who migrated to Canada were in the core working age group between 25 and 54 years and 14.5% 
were between the age of 15 and 24. Children aged 14 and under accounted for the 19.4% of the 
newcomer population and seniors (65 and older) represent 3.3% of all arrivals (136). In summary, 
it is clear that the population of Saskatchewan increased mostly by immigration in the 15 and 54 
age group. 
5.1.1.4 Incidence in self-identified RI 
There is abundant evidence that some chronic diseases such as diabetes (137), 
cardiovascular disease (138,139),  renal disease (140), certain cancers (141,142), and respiratory 
diseases (143) are more frequent in the Canadian Aboriginal population than the general 
population. Our study demonstrated an increased incidence of epilepsy in the self-declared RI 
population. To our knowledge, this is the first study to link epilepsy to the list of frequent chronic 
diseases among the Aboriginal population. 
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The identification of differences in the incidence of epilepsy within different groups is 
crucial to the prevention of and the improvement of the overall outcome in epilepsy in a 
subpopulation. Populations may differ in socioeconomic circumstances, behavior, beliefs, and 
genetics which may result in inequalities unless these differences are taken into account. For 
example, a given population may have: 
1. Differences in education and other socioeconomic markers in accessing healthcare  
2. Difficulty in accessing healthcare in an appropriate language and cultural context 
3. Different disease patterns and/or responses to therapy 
4. Differences in acceptability of treatment interventions 
Awareness of these differences allows focused delivery of health promotion and healthcare 
so that, for example, programs may increase the prevention and detection of epilepsy (such as early 
detection clinics) and provide effective care (144) (such as epilepsy surgery for specific focal 
epilepsies). 
In our study, we found that the incidence of epilepsy in self-declared RI was 1.6 times 
significantly higher than the rest of the population. The highest incidence was seen in males and 
in the 55-59 age group. On the other hand, the lowest incidence of epilepsy was seen in the 80-84 
group age. High incidence rates of epilepsy in RI might be explained by the high incidence of 
traumatic brain injuries in the indigenous population (145), which might be particularly high in 
males. On the other hand, we found, the lowest incidence of epilepsy was seen in the 80-84 RI 
group age group. The lowest rate in this oldest sub-group of RI is consistent with other studies in 
Native American populations, where no incident cases of epilepsy had been reported in the elderly 
population (50,51).  We speculate that the healthy survivor effect (146) may account for this 
 56 
finding, which may be even more noticeable due to inequities in the provision of healthcare 
services for RI resulting in earlier deaths of those with medical comorbidities. For example, elderly 
RI with multiple comorbidities such as diabetes and cardiovascular disease that higher likelihood 
of developing stroke (which is a major risk factor for epilepsy in this group) might only rarely live 
into the oldest age group. 
Regardless of the health indicator explored, Canadian Aboriginals have been shown to 
suffer a disproportionate burden of illness with poor outcomes. This is generally believed to be 
related to their economic and social deprivation as well as long history of colonialism and 
marginalization (147). Despite targeted government health programs, disparities in health between 
the Aboriginal population and the overall Canadian population, remain (147) and we have shown 
that epilepsy is not an exception.  
 
5.1.2 Prevalence 
5.1.2.1 Overall prevalence 
Our study identified 8,880 individuals living with epilepsy in Saskatchewan in 2010. This 
represents an age-standardized prevalence of 8.8 per 1,000 people (95%CI: 8.6, 9.0). The 
prevalence was higher in males (9.2 per 1,000 people) than in females (8.4 per 1,000 people) and 
highest in the 35-39 age group (12.5 per 1,000 people) 
The prevalence in this study is higher than previously reported by  Tellez et al. (9) with 5.2 
per 1,000 people in Saskatchewan (95%CI:4.4, 6.1). This difference may be explained by the 
methodology used to obtain the results. In the study by Tellez, the ascertainment of epilepsy cases 
was self-reported and only covered the population older than 12 years old. In our study, the case 
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ascertainment was based on an algorithm with excellently established metrics ( sensitivity and 
specificity of 88.9% and 92.4% respectively (107) and which also did not rely on self-identification 
of epilepsy. This is of particular interest in the discussion of conflicting research results. All 
throughout history, in practically every culture, epilepsy has been seen as something to be dreaded, 
avoided and disguised. Today, at least in the developed world, this has decreased although it is 
still in recent memory (148) and might affect self-disclosure rates. 
Consistent with this, have been a number of studies indicating that patients with epilepsy 
themselves hold negative attitudes concerning epilepsy and that this self-image contributes to the 
stigma expressed by the community. For example, up to 23.4% of patients in a developed country 
with health record confirmed epilepsy denied having epilepsy (149).  
 
5.1.2.2 Age-specific prevalence  
The prevalence of epilepsy in this study demonstrated a trimodal pattern, with peaks in the 
young, middle age and the oldest. Most other studies have reported a gradual increase in epilepsy 
prevalence toward adolescence or early adulthood, a stable prevalence in the third and fourth 
decades and dropping rates after the fifth decade of life. Only a few studies in Denmark (151), 
USA (116) and the province of Ontario, Canada (8) have shown this trimodal pattern, as we did in 
the prevalence of epilepsy. In these studies the increase in prevalence in older age group could 
have been a reflection of the improved life expectancy of those with epilepsy due to better control 
of the disease, resulting in increased prevalence at older ages during this period (5).  
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5.1.2.2 Temporal trends of the prevalence of epilepsy 
In our study, we found an increase in the prevalence of epilepsy in Saskatchewan over the 
six-year study period. This phenomenon has also been found in the UK, where researchers 
determined temporal trends in the epidemiology of epilepsy over 10 years period, finding that  the 
prevalence of epilepsy increased in both females and males between 1983 and 1993 from 16.7 to 
17 per 1,000 (53).  
Our study population was a dynamic one, i.e., patients entered and left the group at different 
times. The increased prevalence of chronic diseases in this population, therefore, could have been 
due to either an increase in the incidence of the disease or higher survival rates of people with the 
disease (5). Our findings of decreasing incidence of epilepsy in the Saskatchewan population 
allowed us to conclude that the higher survival rate of patients with epilepsy is the answer to the 
increase in prevalence. 
5.1.3 Mortality 
5.1.3.1 Overall mortality and age-specific 
Various measures can be utilized to evaluate mortality. The standard measures proposed 
by the International League Against Epilepsy (ILAE) include mortality rate, and standardized 
mortality ratio (SMR). The SMR is the most widely recognized measure and is used to compare 
rates of death among individuals with epilepsy and a referent population (94).  
By 2005, there were five population-based studies of mortality in the entire epilepsy 
population worldwide (97). These studies (in developed countries) suggested up to threefold 
increases in mortality compared to the general population (SMR 1.6 to 3) and mortality rate 
between 4.8 and 7.8 per 100,000 person-years (97). 
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In this study we found that the SMR for epilepsy in Saskatchewan was up to 2.45 times 
higher than the general population (95%CI 2.33, 2.58) similar to results found in other developed 
countries. We found the highest SMR in children and the lowest was in the elderly group. These 
observations have been seen previously where SMRs have shown an increase with age being the 
reflection of both the low mortality in the reference population and the high mortality in children 
with epilepsy and neurodeficits (97).  
5.2 Strengths and Limitations of the study 
The biggest strength of this study is the excellent provincial health data system which 
provided the primary data files for our study. The health database allows for cross-linkage of 
administrative health data in a generalized province-wide manner. The data collection itself is 
carried out in a systematic, standardized manner (152) and because of its high level of participation 
and retention is highly representative of the population. Finally, because of its high quality and 
comprehensivess, Saskatchewan’s health database system has frequently been used by other 
researchers, including those outside the province, and has been demonstrated in several studies to 
be complete and accurate (153–159).  
We believe that another strength of our study was the algorithm for the case definition of 
epilepsy. There was a previous assessment of the validity of the algorithm for the diagnosis of 
epilepsy using ICD-coded inpatients claims and physician claims in the neighboring province of 
Alberta. This found that the use of two physicians claims or one hospitalization claim in two years 
period was accurate on 93% with a sensitivity of 88.9% (95% CI 85.4- 92.5) and specificity of 
92.4% (95% CI 89.9- 94.9) (101). 
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However, there were some limitations to our study, including our case definition. For 
example, patients with less than two years of age were not included. Other limitations to our study 
resulted from the method of assigning incident cases of epilepsy by ruling out diagnoses in the six-
year period of observation prior the formal study diagnosis. By the definition of epilepsy, epilepsy 
was considered to be resolved if the person had remained seizure–free for more than ten years and 
was off anti-seizure medication for at least five years (1). Therefore, it is possible that a person 
might have been counted as a new case (incident case) of epilepsy even if they had previously had 
epilepsy. Another major limitation was the absence of our dataset of a specific etiology for 
epilepsy, classification of epilepsy and specific causes of death. 
The definition of Registered Indian status was another potential limitation, as this relied on 
self-report, and may, therefore, have resulted in a major number of missing cases.  
Another limitation could be the short period of six years to evaluate secular trends. There 
is no consensus on time required to identify accurately trend changes in chronic diseases. Previous 
studies on secular trends for epilepsy have analyzed periods over ten years. Numerous diseases 
have demonstrated extraordinary changes in incidence over short periods of time, yet chronic 
diseases may evolve over decades.  
However, these results could be preliminary data awaiting for more long-term secular 
trends in incidence, prevalence, and mortality of epilepsy in Canada, with the anticipation of more 
detailed research in the future.  
Because of some of the limitations described above, results from this study should be 
augmented by a direct population survey to screen for potential cases of epilepsy and subsequently 
evaluate patients in person by an epilepsy clinician for confirmation of the diagnosis and to collect 
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additional information. It is also essential to develop a better understanding the meaning of 
seizures, convulsions, and epilepsy in particular cultural settings, exploring the language and ideas 
used to portray seizures and epilepsy. This could help design more culturally appropriate language 
in surveys as well as the approaches to screening (94). 
5.3 Implications 
This study is the first estimate of the incidence rate of epilepsy in the total Canadian 
population. It also provides the first SMR estimate for the general mortality estimate of epilepsy 
in Canada.   
Our results have shown two main points: 1) high incidence of epilepsy among the 
Aboriginal population and high incidence and prevalence among the elderly population.  
These results suggest the urgent need to use research, education, and improvement in 
access and treatment of epilepsy to prevent, delay, and treat this disease, especially in light of the 
increasing prevalence of the Canadian elderly and aboriginal population(160,161)  
In the United States, research in epilepsy is funded at a persistently lower rate than that in 
Alzheimer disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis, and Parkinson disease 
and this disparity cannot be explained by differences in the burden of these diseases in the general 
USA population (162). In Canada, the mandate of the Canadian Institutes of Health Research 
(CIHR)  is to "excel, according to internationally accepted standards of scientific excellence, in 
the creation of new knowledge and its translation into improved health for Canadians, more 
effective health services and products and a strengthened Canadian health care system” (163). 
However, epilepsy is not included in the priority areas of the Neuroscience, Mental Health and 
Addiction (164). 
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Hospitals and regional health authorities in Canada and elsewhere are facing significant 
resource allocation challenges. Priorities based on clinical impact, community needs, and resource 
implications must be set among competing opportunities because demand for health care exceeds 
available resources (165). Epilepsy needs to be one of the high health priorities in the province of 
Saskatchewan. 
This study, therefore, provides information about core indicators of public health and 
healthcare needs of the population as well as crucial inputs for the burden of epilepsy in 
Saskatchewan and Canada.  
 
5.4 Conclusion 
The purpose of the current study was to determine the overall incidence rate, prevalence, 
and mortality of epilepsy in the province of Saskatchewan, Canada describing them annually and 
over a period of six years and estimating their crude, age-standardized and stratum measures. In 
this research study, the use of administrative data from the province of Saskatchewan and the use 
of a previously validated epilepsy algorithm provided the necessary information to measure these 
key morbidity and mortality indicators in epilepsy for this Canadian province. 
Although incidence, prevalence, and mortality of epilepsy have been described all around 
the world, Canada lacks on information on incidence and mortality in all age group, in subgroups, 
and over a period of time (trends).  This study described for the first time the crude and age-
standardized incidence of epilepsy in the province of Saskatchewan as well as the incidence of 
epilepsy in self-identified Registered Indian subgroup and standardized mortality ratio for 
epilepsy. Finally, the prevalence of epilepsy was described.  
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This study found that the overall and age-standardized incidence and prevalence of 
epilepsy were in the range reported in other developed countries empathizing a higher incidence 
in the elderly population. Also, the SMR was similar than previous reports. However, important 
differences were found in the incidence’s trends and previous prevalence rates of epilepsy in 
Saskatchewan. This study has identified an overall decrease incidence of epilepsy over time only 
seen in countries with universal health care (Finland, Sweden, and the UK). However, this data is 
preliminary due to a short follow-up period and needs more comprehensive research in the future. 
On the other hand, the prevalence of epilepsy in this study is greater than the previous measure of 
prevalence in the province, which may be explained by the methodology used in each study. 
 One of the more significant findings to emerge from this study is that the incidence of 
epilepsy in self-declared RI is higher than the rest of the population and that the incidence of 
epilepsy in the elderly self-declared RI was low. 
This resulted in our finding that epilepsy is the second most frequent neurological disease 
in Saskatchewan affecting all population groups, but especially Aboriginal and elderly 
populations. Its incidence is higher than multiple sclerosis (MS) (incidence of 9.5 per 100,000) 
(166), dementia and Alzheimer’s disease (incidence of 0.73 per 100,000) (167) and its prevalence 
is higher than MS (prevalence of 2.8 per 1,000 people) (166), Alzheimer’s (prevalence of 28 per 
1,000 people) (167)and Parkinson’s disease (prevalence of 2, per 1,000 people). Also, people with 
epilepsy died more frequently than the rest of the population. 
In a health system that is facing significant resources allocation challenges, identifying 
health priorities is a key for success, and epilepsy has to be one of these priorities.  
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